Authors : Anusha Gupta, Anusha Gupta, Sunil Kumar, Sunil Kumar, Saurav Chaturvedi, Saurav Chaturvedi, Apoorva Nirmal, Apoorva Nirmal
DOI : 10.18231/2348-7240.2018.0019
Volume : 5
Issue : 2
Year : 0
Page No : 79-80
Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia.
Keywords: Drug-induced pigmentation, Imatinib-mesylate, Melasma, Chronic myeloid leukemia.